查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1670878

2025 年全球放射性药物治疗诊断学市场报告

Radiopharmaceutical Theranostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年放射性药物治疗诊断学的市场规模将快速成长。到 2029 年，这一数字将成长到 57.6 亿美元，年复合成长率（CAGR）为 15.2%。预测期内的成长归因于生物标记的发现和检验、基因组和蛋白质组技术、精准放射治疗的发展、多学科合作以及患者的倡导和支持。预测期内的关键趋势包括伦理和法律考虑、远端医疗、以患者为中心的护理、放射性药物的定制以及奈米治疗诊断学的发展。

随着癌症发病率的不断上升，放射性药物治疗诊断学市场预计将出现成长。癌症的特征是细胞异常增殖、侵袭和扩散，需要有针对性和个人化的方法才能有效治疗。放射性药物治疗诊断学在癌症治疗中发挥关键作用，可提供精准、个人化的解决方案。仅在美国，美国癌症协会估计，2023 年将诊断出 190 万例新癌症病例，约 609,820 人将死于该疾病。其中，大多数（88%）诊断的患者年龄在 50 岁或以上。癌症发生率的上升是推动放射性药物治疗诊断学市场扩张的关键因素。

增加医疗保健支出在放射性药物治疗诊断学市场未来成长中发挥关键作用。政府的支持措施以及放射性药物治疗诊断学领域研发的津贴和资助正在刺激创新并促进新产品的商业化。例如，2024年10月，美国联邦机构医疗保险和医疗补助服务中心报告称，处方药支出将增加8.4%，到2022年达到4059亿美元，高于2021年的6.8%的增幅。因此，医疗成本的上涨预计将推动放射性药物治疗诊断学市场的发展。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第 4 章 市场：宏观经济情景，包括利率、通膨、地缘政治、新冠疫情以及復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球放射性药物治疗诊断学PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素、限制因素）
  • 最终用途产业分析
  • 全球放射性药物治疗诊断学市场：成长率分析
  • 全球放射性药物治疗诊断学市场表现：规模与成长，2019 年至 2024 年
  • 全球放射性药物治疗诊断学市场预测：2024-2029 年及 2034 年规模与成长
  • 全球放射性药物治疗诊断学总目标市场 (TAM)

第六章 市场细分

  • 全球放射性药物治疗诊断学市场（按产品类型、性能和预测）2019-2024 年、2024-2029 年、2034 年
  • α发射体
  • 贝塔发射体
  • 正子断层扫描 (PET) 示踪剂
  • 全球放射性药物治疗诊断学市场（依来源、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 核子反应炉
  • 迴旋加速器
  • 全球放射性药物治疗诊断学市场（按放射性同位素划分）、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • Technetium-99
  • 镓-68
  • 碘-131
  • 碘-123
  • 18 楼
  • Y-90
  • 镏(Lu) 177
  • 铜（Cu） 67
  • 铜（Cu） 64
  • 其他放射内视镜
  • 全球放射性药物治疗诊断学市场（依适应症、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 其他适应症
  • 全球放射性药物治疗诊断学市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 诊断影像中心
  • 学术研究所
  • 其他最终用户
  • 全球放射性药物治疗诊断学市场、α发射体体细分、产品类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 锕 225
  • 镭 223
  • 铋 213
  • 其他发射α射线的放射性药物
  • 全球放射性药物治疗诊断学市场，β 发射体依产品类型细分，实际及预测，2019-2024 年，2024-2029 年，2034 年
  • 碘-131
  • 镏177
  • 钇90
  • 其他β射线放射性药物
  • 全球放射性药物治疗诊断学市场、正子断层扫描 (PET) 示踪剂细分（按产品类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 氟脱氧葡萄糖 (FDG)
  • 镓-68
  • 碳 11
  • 其他 PET 示踪剂

第七章 区域和国家分析

  • 全球放射性药物治疗诊断学市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球放射性药物治疗诊断学市场：依国家、表现及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第 17 章 德国市场

第 18 章 法国市场

第 19 章：义大利市场

第 20 章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第 25 章：加拿大市场

第26章 南美洲市场

第 27 章：巴西市场

第28章 中东市场

第 29 章：非洲市场

第 30 章竞争格局与公司概况

  • 放射性药物治疗诊断学市场：竞争格局
  • 放射性药物治疗诊断学市场：公司简介
    • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • China Grand Pharmaceutical & Healthcare. Overview, Products and Services, Strategy and Financial Analysis
    • Lantheus Medical Imaging Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Curium Pharma
  • Advanced Accelerator Applications
  • Telix Pharmaceuticals Ltd.
  • Bracco Imaging SpA
  • NTP Radioisotopes SOC Ltd.
  • Navidea Biopharmaceuticals Inc.
  • Jubilant DraxImage Inc.
  • NorthStar Medical Radioisotopes LLC
  • Blue Earth Diagnostics Ltd.
  • Precirix NV
  • SpectronRx
  • Viewpoint Molecular Targeting Inc.
  • NuView Life Sciences
  • Alpha-9 Theranostics Inc.
  • RadioMedix Inc

第 32 章 全球市场竞争基准化分析与仪表板

第33章 重大併购

第 34 章 近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029 年放射性药物治疗诊断学市场：提供新机会的国家
  • 2029 年放射性药物治疗诊断学市场：细分市场将带来新机会
  • 2029 年放射性药物治疗诊断学市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第 36 章 附录

简介目录
Product Code: r25248

Radiopharmaceutical theranostics involves a combined medical approach that integrates therapeutics (treatment) and diagnostics (diagnosis) through the utilization of radiopharmaceuticals. These substances are employed for patient diagnosis, therapy, and personalized management.

The primary product categories within radiopharmaceutical theranostics include alpha emitters, beta emitters, and positron emission tomography (PET) tracers. Alpha emitters are radioactive substances emitting alpha particles, characterized by high-energy particles consisting of two protons and two neutrons. Various sources for these include nuclear reactors and cyclotrons, and the diverse radioisotopes encompass technetium-99, gallium-68, iodine-131, iodine-123, 18F, Y-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, among others. These radiopharmaceuticals find applications in oncology, cardiology, neurology, and other medical indications, and are utilized by various end-users, including hospitals, diagnostic imaging centers, academic and research institutes, and others.

The radiopharmaceutical theranostics market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceutical theranostics market statistics, including radiopharmaceutical theranostics industry global market size, regional shares, competitors with a radiopharmaceutical theranostics market share, detailed radiopharmaceutical theranostics market segments, market trends, and opportunities, and any further data you may need to thrive in the radiopharmaceutical theranostics industry. This radiopharmaceutical theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $2.88 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to radiopharmaceutical development, clinical research advances, investment in research, regulatory approval, and nuclear medicine progress

The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $5.76 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to biomarker discovery and validation, genomic and proteomic technologies, precision radiotherapy development, interdisciplinary collaborations, patient advocacy and support. Major trends in the forecast period include ethical and legal considerations, telemedicine in theranostics, patient-centric care, radiopharmaceutical customization, and nano-theranostics development.

The radiopharmaceutical theranostics market is poised for growth, driven by the increasing incidence of cancer. Cancer, characterized by abnormal cell growth that can invade and spread, necessitates targeted and personalized approaches for effective treatment. Radiopharmaceutical theranostics plays a crucial role in cancer treatment, offering precision and personalized solutions. In the US alone, the American Cancer Society estimates that 1.9 million new cancer cases may be diagnosed in 2023, resulting in approximately 609,820 deaths. The majority of these diagnoses, 88%, are expected to be in individuals aged 50 and above. The rising prevalence of cancer is a key factor fueling the expansion of the radiopharmaceutical theranostics market.

Increasing healthcare expenditure is playing a significant role in the growth of the radiopharmaceutical theranostics market in the future. Supportive government initiatives, along with grants and funding for research and development in the area of radiopharmaceutical theranostics, promote innovation and facilitate the commercialization of new products. For example, in October 2024, the Centers for Medicare & Medicaid Services, a federal agency in the US, reported that prescription drug spending increased by 8.4%, reaching $405.9 billion in 2022, surpassing the 6.8% growth seen in 2021. Consequently, the rising healthcare expenditure is expected to propel the radiopharmaceutical theranostics market.

Leading companies in the radiopharmaceutical theranostics market are embracing a strategic partnership model to create innovative therapies. These collaborations allow radiopharmaceutical theranostics firms to pool resources and expertise, improve research and development capabilities, broaden market reach, and speed up commercialization, ultimately fostering innovation and growth within the industry. For example, in March 2023, Radiopharm Theranostics, a biotechnology company based in Australia, formed a partnership with Pharma15 Corporation, a US-based venture, to develop next-generation therapeutic radiopharmaceuticals aimed at prostate cancer. The focus is on overcoming resistance to current PSMA-targeted therapies while improving selectivity to reduce toxicity in healthy tissues.

Companies operating in the radiopharmaceutical theranostics market are also focusing on the development of theranostics for cancer treatment. Theranostic approaches aim to provide targeted therapies and diagnostic solutions for rare diseases, particularly for patients with limited treatment options such as cancer. In November 2023, GE HealthCare Technologies Inc. launched theranostic solutions for cancer, marking a significant stride in precision medicine. Theranostics utilizes therapeutic agents in conjunction with imaging technology to identify and target cancer cells for destruction.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company, acquired Pharma15 Corporation for $4 million. This strategic move positions Radiopharm to explore next-generation radiopharmaceuticals for prostate cancer treatment, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in radio-immuno-theranostics platforms and pharmaceutical products' development, aligning with Radiopharm's focus on advancing radiopharmaceutical products.

Major companies operating in the radiopharmaceutical theranostics market include Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

North America was the largest region in the radiopharmaceutical theranostics market in 2024. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiopharmaceutical theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmaceutical theranostics market includes revenues earned by providing genetic testing, targeted therapy services, contract development, and manufacturing services, consultation and interpretation, and personalized therapeutic interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceutical Theranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiopharmaceutical theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceutical theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The radiopharmaceutical theranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Alpha Emitters; Beta Emitters; Positron Emission Tomography (PET) Tracers
  • 2) By Source: Nuclear Reactors; Cyclotrons
  • 3) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; 18F; Y-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioscopes
  • 4) By Indication: Oncology; Cardiology; Neurology; Other Indications
  • 5) By End User: Hospitals; Diagnostic Imaging Centers; Academic And Research Institutes; Other End Users
  • Subsegments:
  • 1) By Alpha Emitters: Actinium-225; Radium-223; Bismuth-213; Other Alpha-Emitting Radiopharmaceuticals
  • 2) By Beta Emitters: Iodine-131; Lutetium-177; Yttrium-90; Other Beta-Emitting Radiopharmaceuticals
  • 3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG); Gallium-68; Carbon-11; Other PET Tracers
  • Companies Mentioned: Cardinal Health Inc.; GE HealthCare Technologies Inc.; Bayer AG; China Grand Pharmaceutical & Healthcare.; Lantheus Medical Imaging Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radiopharmaceutical Theranostics Market Characteristics

3. Radiopharmaceutical Theranostics Market Trends And Strategies

4. Radiopharmaceutical Theranostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Radiopharmaceutical Theranostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Radiopharmaceutical Theranostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Radiopharmaceutical Theranostics Market Growth Rate Analysis
  • 5.4. Global Radiopharmaceutical Theranostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Radiopharmaceutical Theranostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Radiopharmaceutical Theranostics Total Addressable Market (TAM)

6. Radiopharmaceutical Theranostics Market Segmentation

  • 6.1. Global Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Positron Emission Tomography (PET) Tracers
  • 6.2. Global Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nuclear Reactors
  • Cyclotrons
  • 6.3. Global Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • 18F
  • Y-90
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Copper (Cu) 64
  • Other Radioscopes
  • 6.4. Global Radiopharmaceutical Theranostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Neurology
  • Other Indications
  • 6.5. Global Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic And Research Institutes
  • Other End Users
  • 6.6. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Alpha Emitters, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Actinium-225
  • Radium-223
  • Bismuth-213
  • Other Alpha-Emitting Radiopharmaceuticals
  • 6.7. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Beta Emitters, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iodine-131
  • Lutetium-177
  • Yttrium-90
  • Other Beta-Emitting Radiopharmaceuticals
  • 6.8. Global Radiopharmaceutical Theranostics Market, Sub-Segmentation Of Positron Emission Tomography (PET) Tracers, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fluorodeoxyglucose (FDG)
  • Gallium-68
  • Carbon-11
  • Other PET Tracers

7. Radiopharmaceutical Theranostics Market Regional And Country Analysis

  • 7.1. Global Radiopharmaceutical Theranostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Radiopharmaceutical Theranostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radiopharmaceutical Theranostics Market

  • 8.1. Asia-Pacific Radiopharmaceutical Theranostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radiopharmaceutical Theranostics Market

  • 9.1. China Radiopharmaceutical Theranostics Market Overview
  • 9.2. China Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radiopharmaceutical Theranostics Market

  • 10.1. India Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radiopharmaceutical Theranostics Market

  • 11.1. Japan Radiopharmaceutical Theranostics Market Overview
  • 11.2. Japan Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radiopharmaceutical Theranostics Market

  • 12.1. Australia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radiopharmaceutical Theranostics Market

  • 13.1. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radiopharmaceutical Theranostics Market

  • 14.1. South Korea Radiopharmaceutical Theranostics Market Overview
  • 14.2. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radiopharmaceutical Theranostics Market

  • 15.1. Western Europe Radiopharmaceutical Theranostics Market Overview
  • 15.2. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radiopharmaceutical Theranostics Market

  • 16.1. UK Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radiopharmaceutical Theranostics Market

  • 17.1. Germany Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radiopharmaceutical Theranostics Market

  • 18.1. France Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radiopharmaceutical Theranostics Market

  • 19.1. Italy Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radiopharmaceutical Theranostics Market

  • 20.1. Spain Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radiopharmaceutical Theranostics Market

  • 21.1. Eastern Europe Radiopharmaceutical Theranostics Market Overview
  • 21.2. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radiopharmaceutical Theranostics Market

  • 22.1. Russia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radiopharmaceutical Theranostics Market

  • 23.1. North America Radiopharmaceutical Theranostics Market Overview
  • 23.2. North America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radiopharmaceutical Theranostics Market

  • 24.1. USA Radiopharmaceutical Theranostics Market Overview
  • 24.2. USA Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radiopharmaceutical Theranostics Market

  • 25.1. Canada Radiopharmaceutical Theranostics Market Overview
  • 25.2. Canada Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radiopharmaceutical Theranostics Market

  • 26.1. South America Radiopharmaceutical Theranostics Market Overview
  • 26.2. South America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radiopharmaceutical Theranostics Market

  • 27.1. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radiopharmaceutical Theranostics Market

  • 28.1. Middle East Radiopharmaceutical Theranostics Market Overview
  • 28.2. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radiopharmaceutical Theranostics Market

  • 29.1. Africa Radiopharmaceutical Theranostics Market Overview
  • 29.2. Africa Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radiopharmaceutical Theranostics Market Competitive Landscape And Company Profiles

  • 30.1. Radiopharmaceutical Theranostics Market Competitive Landscape
  • 30.2. Radiopharmaceutical Theranostics Market Company Profiles
    • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. China Grand Pharmaceutical & Healthcare. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Lantheus Medical Imaging Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Radiopharmaceutical Theranostics Market Other Major And Innovative Companies

  • 31.1. Curium Pharma
  • 31.2. Advanced Accelerator Applications
  • 31.3. Telix Pharmaceuticals Ltd.
  • 31.4. Bracco Imaging S.p.A
  • 31.5. NTP Radioisotopes SOC Ltd.
  • 31.6. Navidea Biopharmaceuticals Inc.
  • 31.7. Jubilant DraxImage Inc.
  • 31.8. NorthStar Medical Radioisotopes LLC
  • 31.9. Blue Earth Diagnostics Ltd.
  • 31.10. Precirix NV
  • 31.11. SpectronRx
  • 31.12. Viewpoint Molecular Targeting Inc.
  • 31.13. NuView Life Sciences
  • 31.14. Alpha-9 Theranostics Inc.
  • 31.15. RadioMedix Inc

32. Global Radiopharmaceutical Theranostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radiopharmaceutical Theranostics Market

34. Recent Developments In The Radiopharmaceutical Theranostics Market

35. Radiopharmaceutical Theranostics Market High Potential Countries, Segments and Strategies

  • 35.1 Radiopharmaceutical Theranostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Radiopharmaceutical Theranostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Radiopharmaceutical Theranostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer